These significant variations in DR4/5 expression for similar treatment regimens could also be explained by differences in the receptor activity following TRAIL binding.[64] Research has also shown that DR5 promotes cancer cell invasion and metastasis, so increases in DR5 expression and proliferation in response to some of the treatment intervals could indicate a fraction of tumor cells re‐populating in regions of the tumor that previously underwent apoptosis from the treatment, since tumors were resected 41 days after the second treatment and no additional doses were administered.[73, 74]. The gene discussed is TNFSF10; the disease is cancer.